Canada markets open in 18 minutes

Adverum Biotechnologies, Inc. (ADVM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.00+0.21 (+2.15%)
At close: 04:00PM EDT
10.45 +0.45 (+4.50%)
Pre-Market: 09:03AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.79
Open10.11
Bid9.97 x 400
Ask10.05 x 400
Day's Range9.50 - 10.15
52 Week Range7.40 - 29.70
Volume372,851
Avg. Volume330,547
Market Cap207.549M
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Adverum Biotechnologies to Participate in Upcoming May Investor Conferences

    REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright

  • GlobeNewswire

    Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

    REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present the 26-week landmark interim analysis from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) at the American Society of Retina Specialists (

  • GlobeNewswire

    Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates

    - Preliminary LUNA data presented at the Annual Meeting of the Macula Society support potential best-in-class clinical activity and an encouraging safety profile in patients with wet AMD - - Completed $127.5 million private placement financing with new and existing institutional investors - - Cash runway expected into late 2025 – - 1-for-10 reverse stock split to be effective March 21, 2024 - REDWOOD CITY, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a